High
0.910
Open
0.890
VWAP
0.89
Vol
13.91K
Mkt Cap
65.11M
Low
0.8631
Amount
12.36K
EV/EBITDA(TTM)
--
Total Shares
71.55M
EV
68.91M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
Show More
Valuation Metrics
The current forward P/E ratio for Citius Oncology Inc (CTOR.O) is -6.70, compared to its 5-year average forward P/E of -1.39. For a more detailed relative valuation and DCF analysis to assess Citius Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.39
Current PE
-6.70
Overvalued PE
0.83
Undervalued PE
-3.61
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.74
Current PS
1.11
Overvalued PS
2.17
Undervalued PS
-0.70
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+1845.87%
-7.47M
Operating Profit
FY2025Q2
YoY :
-3164.05%
-7.74M
Net Income after Tax
FY2025Q2
YoY :
-375.00%
-0.11
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTOR News & Events
Events Timeline
(ET)
2025-02-06
07:59:06
Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir
2025-01-07 (ET)
2025-01-07
07:13:06
Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25
2025-01-06 (ET)
2025-01-06
06:52:15
Citius Oncology to explore strategic alternatives
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
05-23BenzingaThis Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Preview
9.5
05-14PRnewswireCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Preview
1.0
05-05PRnewswireCitius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Sign Up For More News
People Also Watch
LTBR
Lightbridge Corp
15.200
USD
+42.59%
INVE
Identiv Inc
3.300
USD
-0.30%
HSPO
Horizon Space Acquisition I Corp
12.070
USD
+0.99%
MNOV
MediciNova Inc
1.410
USD
+2.17%
PAVS
Paranovus Entertainment Technology Ltd
1.000
USD
-6.54%
DTSQ
DT Cloud Star Acquisition Corp
0
USD
-0.78%
COYA
Coya Therapeutics Inc
5.900
USD
+3.33%
ALOT
AstroNova Inc
9.010
USD
-1.10%
ADVM
Adverum Biotechnologies Inc
2.210
USD
-0.90%
FSHP
Flag Ship Acquisition Corp
10.400
USD
0.00%
FAQ
What is Citius Oncology Inc (CTOR) stock price today?
The current price of CTOR is 0.91 USD — it has increased 0 % in the last trading day.
What is Citius Oncology Inc (CTOR)'s business?
What is the price predicton of CTOR Stock?
What is Citius Oncology Inc (CTOR)'s revenue for the last quarter?
What is Citius Oncology Inc (CTOR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Citius Oncology Inc (CTOR)'s fundamentals?
How many employees does Citius Oncology Inc (CTOR). have?